{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:49:01Z","timestamp":1793911741633,"version":"4.8.0"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jtim-2025-0018_s_005\">\n                  <jats:title>Background and Objectives<\/jats:title>\n                  <jats:p>Haploidentical stem cell transplantation (haplo-HSCT) has demonstrated promising results in patients without severe comorbidities. There is also an increasing need for haplo-HSCT in patients with severe comorbidities. However, the high risk of treatment-related mortality (TRM) hindered its extensive application. We aimed to investigate a novel conditioning regimen (Bu\/Flu\/Cy\/ATG) followed by haplo-HSCT in patients with severe comorbidities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jtim-2025-0018_s_006\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective, single-arm clinical trial was performed at Peking University Institute of Hematology, China. Patients were enrolled if they were (1) diagnosed with acute leukemia, myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML); (2) patients with no HLA-matched sibling donor or matched unrelated donor available but with a haplo-HSCT donor; (3) patients with hematopoietic cell transplantation comorbidity index (HCT-CI) scores \u22653. The primary endpoint was 2-year TRM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jtim-2025-0018_s_007\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From June 2018 to November 2022, a total of 72 patients were enrolled. All patients achieved neutrophil engraftment. The cumulative incidence of grade II\u2013IV acute graft-versus-host disease (aGVHD) at day 100 was 20.8%. The cumulative incidences of cytomegalovirus (CMV) viremia and Epstein\u2012Barr (EB) viremia at day 100 were 72.2% and 31.9%, respectively. The cumulative incidence of 2-year TRM was 25.1%. The cumulative incidence of 2-year relapse was 8.6%. The probabilities of 2-year overall survival and leukemia-free survival were 71.9% and 65.6%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jtim-2025-0018_s_008\">\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study suggested that a novel conditioning regimen followed by haploidentical HSCT might be a promising option for patients with severe comorbidities. The study was registered as a clinical trial (NCT03412409).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jtim-2025-0018","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T20:50:46Z","timestamp":1747601446000},"page":"128-137","source":"Crossref","is-referenced-by-count":9,"title":["A novel and safe protocol for patients with severe comorbidity who undergo haploidentical hematopoietic stem cell transplantation: A single-center prospective study"],"prefix":"10.1515","volume":"13","author":[{"given":"Wei","family":"Sun","sequence":"first","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Sun","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengrong","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhua","family":"Yan","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing , China"},{"name":"Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"2025052801302723189_j_jtim-2025-0018_ref_001","doi-asserted-by":"crossref","unstructured":"Chang YJ, Wang Y, Xu LP, Zhang X, Chen H, Chen YH, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol 2020;13:27.","DOI":"10.1186\/s13045-020-00860-y"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_002","doi-asserted-by":"crossref","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015;125:3956\u20133962.","DOI":"10.1182\/blood-2015-02-627786"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_003","doi-asserted-by":"crossref","unstructured":"Mo XD, Xu LP, Liu DH, Zhang XH, Chen H, Chen YH, et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol 2013;88:497\u2013502.","DOI":"10.1002\/ajh.23443"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_004","doi-asserted-by":"crossref","unstructured":"Chang YJ, Wang HT, Xu LP, Wang Y, Liu KY, Zhang XH, et al Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leuk Lymphoma 2016;57:2133\u20132139.","DOI":"10.3109\/10428194.2015.1124990"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_005","doi-asserted-by":"crossref","unstructured":"McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043\u20132048.","DOI":"10.1182\/blood-2002-06-1860"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_006","doi-asserted-by":"crossref","unstructured":"Bornh\u00e4user M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003;102:820\u2013826.","DOI":"10.1182\/blood-2002-11-3567"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_007","doi-asserted-by":"crossref","unstructured":"de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004;104:857\u2013864.","DOI":"10.1182\/blood-2004-02-0414"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_008","unstructured":"Wang FR, Huang XJ, Liu DH, Chen H, Wang Y, Tang FF, et al. [The efficacy and safety of modified busulfan\/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies]. Zhonghua Nei Ke Za Zhi 2013;52:1028\u20131032."},{"key":"2025052801302723189_j_jtim-2025-0018_ref_009","doi-asserted-by":"crossref","unstructured":"Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, et al. Favorable outcomes of intravenous busulfan, fludarabine, and 400cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and\/or co-morbidities. Int J Hematol 2010;92:342\u2013350.","DOI":"10.1007\/s12185-010-0649-y"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_010","doi-asserted-by":"crossref","unstructured":"Sun YQ, Han TT, Wang Y, Yan CH, Wang FR, Wang ZD, et al. Haploidentical stem cell transplantation with a novel conditioning regimen in older patients: a prospective single-arm phase 2 study. Front Oncol 2021;11:639502.","DOI":"10.3389\/fonc.2021.639502"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_011","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912\u20132919.","DOI":"10.1182\/blood-2005-05-2004"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_012","doi-asserted-by":"crossref","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009;15:257\u2013265.","DOI":"10.1016\/j.bbmt.2008.11.025"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_013","doi-asserted-by":"crossref","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplantation 2006;38:291\u2013297.","DOI":"10.1038\/sj.bmt.1705445"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_014","doi-asserted-by":"crossref","unstructured":"Wang Y, Chen H, Chen J, Han M, Hu J, Hu J, et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett 2018;438:63\u201375.","DOI":"10.1016\/j.canlet.2018.08.030"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_015","doi-asserted-by":"crossref","unstructured":"Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, et al. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophos-phamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant 2012;18:1007\u20131011.","DOI":"10.1016\/j.bbmt.2012.04.014"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_016","doi-asserted-by":"crossref","unstructured":"Han TT, Xu LP, Liu DH, Liu KY, Fu HX, Zhao XY, et al. Cytomegalovirus is a potential risk factor for late-onset hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2014;89:55\u201361.","DOI":"10.1002\/ajh.23584"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_017","doi-asserted-by":"crossref","unstructured":"Pei XY, Zhao XY, Chang YJ, Liu J, Xu LP, Wang Y, et al. Cytomegalovirusspecific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis 2017;216:945\u2013956.","DOI":"10.1093\/infdis\/jix357"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_018","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825\u2013828."},{"key":"2025052801302723189_j_jtim-2025-0018_ref_019","doi-asserted-by":"crossref","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945\u2013956.","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_020","doi-asserted-by":"crossref","unstructured":"Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562\u20131568.","DOI":"10.1200\/JCO.1988.6.10.1562"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_021","doi-asserted-by":"crossref","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695\u2013706.","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO;2-F"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_022","doi-asserted-by":"crossref","unstructured":"Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, et al. Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplantation 2019;54:432\u2013441.","DOI":"10.1038\/s41409-018-0279-1"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_023","doi-asserted-by":"crossref","unstructured":"Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K, et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant 2015;21:1646\u20131652.","DOI":"10.1016\/j.bbmt.2015.06.008"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_024","doi-asserted-by":"crossref","unstructured":"Solh MM, Hinojosa G, Laporte J, Solomon SR, Morris LE, Zhang X, et al. A phase II trial of melphalan based reduced-intensity conditioning for transplantation of T-replete HLA-haploidentical peripheral blood stem cells with posttransplant cyclophosphamide in patients with hematologic malignancies. Adv Hematol 2021;2021:8868142.","DOI":"10.1155\/2021\/8868142"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_025","doi-asserted-by":"crossref","unstructured":"Higuchi K, Sawada A, Kondo O, Okada Y, Tsujimoto H, Ioi A, et al. HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed\/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis. Int J Hematol 2022115:406\u2013413.","DOI":"10.1007\/s12185-021-03270-z"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_026","doi-asserted-by":"crossref","unstructured":"Pan M, Wu Y, Yang L, Zhu P, Shi J, Lai X, et al. Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients. Ann Hematol 2024;103:3105\u20133119.","DOI":"10.1007\/s00277-024-05819-4"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_027","doi-asserted-by":"crossref","unstructured":"Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, et al. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide for AML undergoing HLA-haploidentical hematopoietic cell transplantation: a multicenter randomized phase III trial. J Clin Oncol 2023;41:4632\u20134642.","DOI":"10.1200\/JCO.23.00101"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_028","doi-asserted-by":"crossref","unstructured":"Liu H, Zhai X, Song Z, Sun J, Xiao Y. Nie D, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol 2013;6:15.","DOI":"10.1186\/1756-8722-6-15"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_029","doi-asserted-by":"crossref","unstructured":"Zhang WP, Wang ZW, Hu XX, Chen J, Yang D, Song XM, et al. Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study. Bone Marrow Transplant 2019;54:894\u2013902.","DOI":"10.1038\/s41409-018-0356-5"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_030","doi-asserted-by":"crossref","unstructured":"Sun YQ, Xu LP, Zhang XH, Liu DH, Chen H, Wang Y, et al. A retrospective comparison of BU-fludarabine and BU\u2013CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. Bone Marrow Transplant 2015;50:601\u2013603.","DOI":"10.1038\/bmt.2014.303"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_031","doi-asserted-by":"crossref","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett 2024;605:217264.","DOI":"10.1016\/j.canlet.2024.217264"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_032","doi-asserted-by":"crossref","unstructured":"Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbas, MH, et al. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma 2011;52:137\u2013141.","DOI":"10.3109\/10428194.2010.524328"},{"key":"2025052801302723189_j_jtim-2025-0018_ref_033","doi-asserted-by":"crossref","unstructured":"Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, et al. Risk factors and clinical outcomes of Epstein\u2013Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. Ann Hematol 2019;98:2163\u20132177.","DOI":"10.1007\/s00277-019-03742-7"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0018\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0018\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T01:31:11Z","timestamp":1748395871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0018\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,18]]},"published-print":{"date-parts":[[2025,5,23]]}},"alternative-id":["10.1515\/jtim-2025-0018"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2025-0018","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}